Liver Lesion Articles & Analysis
5 news found
For patients with cancer in the liver and severely impaired kidney function respondents currently prefer not to use a contrast agent when performing an MRI (unenhanced), even though this reduces the ability to detect and visualize cancer lesions. ...
Orviglance is Ascelia Pharma’s oral investigational MRI imaging agent used in the visualization of cancer in the liver and is currently in Phase 3 development. The Hepatic Impairment Study evaluates if patients with different degrees of hepatic impairment can tolerate Orviglance since Orviglance is selectively taken up and excreted by the liver. The study ...
As communicated earlier, the results showed that a higher number of liver lesions was detected by the three independent readers for Orviglance compared to the liver-specific gadolinium contrast agent. All three readers were also able to see smaller lesions with Orviglance compared to gadolinium. With respect to ...
As communicated earlier, the comparison study versus the gadolinium contrast agent showed that MRI enhanced with the contrast agent Orviglance (former working name Mangoral) was as effective as the gadolinium contrast agent gadobenate dimeglumine (Multihance) in terms of visualization of lesions and number of detected lesions in the liver. The ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. This partnership seeks to improve the detection of drug-induced liver ...
ByPoietis